profit from every $100 of sales.
$0$100
Claritev
$26.82-0.30% today
-39.3% in 1 year
1-year low $13.471-year high $54.87
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Claritev sold, what it kept, and what it did with the cash.
Sales went from $1.08 billion in 2022 to $965 million in 2025, with -$284 million of profit last year.
SalesProfit
Claritev vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Claritev | No profit yet | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Claritev's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,080 | 962 | 931 | 965 | |
| 876 | 666 | 627 | 649 | |
| 334 | 171 | 108 | 45 | |
| 158 | 652 | -1,008 | 467 | |
| -573 | -92 | -1,646 | -284 | |
| -36.00 | -5.69 | -101.92 | -17.30 | |
| 81.1% | 69.3% | 67.4% | 67.2% | |
| 31.0% | 17.8% | 11.6% | 4.7% | |
| -53.1% | -9.5% | -176.9% | -29.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7,371 | 6,965 | 5,151 | 4,888 |
| Cash | 334 | 72 | 17 | 17 |
| Total debt | 4,782 | 4,568 | 4,541 | 4,616 |
| Total liabilities | 5,581 | 5,256 | 5,067 | 5,056 |
| 1,791 | 1,709 | 84 | -174 | |
| 16 | 16 | 16 | 16 | |
| -3.1% | 2.8% | -24.7% | 0.3% | |
| -32.0% | -5.4% | -1,958.8% | 163.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 372 | 172 | 108 | 117 | |
| 90 | 109 | 118 | 130 | |
| 283 | 63 | -11 | -12 | |
| Dividends paid | – | – | – | – |
| 0 | 15 | 10 | 0 | |
| 17 | 18 | 27 | 28 |
Valuation
- –
- –
- –
- -2.1×
- 0.5×
- –
- 10.8×
- -2.7%
- -62.1%
- 0.0%
Profitability
- 67.2%
- 4.7%
- -29.4%
- 53.0%
- 0.8%
- -10.1%
- 205.8%
- -5.9%
- 0.9%
- –
Growth
- −3.7%
- –
- −16.8%
- –
- +0.2%
Financial health
- 8.8×
- -19.11
- 95.2%
- 0.1×
- 1.28
- 1.28
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 964
Bottom 31%of 898
Bottom 11%of 911
Bottom 22%of 991
What analysts expect
- Average price target
- $32.00
- Range
- $28.00 – $38.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -4.41 | -3.81 | −15.7% |
| Feb 23, 2026 | -4.88 | 0.85 | −674.1% |
| Nov 7, 2025 | -4.07 | -3.12 | −30.4% |
| Aug 6, 2025 | 0.32 | -2.69 | +111.9% |
| May 8, 2025 | -3.43 | -2.20 | −55.9% |
| Feb 25, 2025 | -5.14 | -9.81 | +47.6% |
| Aug 1, 2024 | -35.60 | -2.22 | −1,503.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
13No pass
Benjamin Graham
13No pass
Philip Fisher
35No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
16No pass
Questions about Claritev
Is Claritev a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Claritev AI analysis
What does Claritev do?
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. It is in Medical - Healthcare Information Services.
Does Claritev pay a dividend?
No. Claritev does not pay a dividend at the moment.
Is Claritev stock halal?
No. Claritev does not pass our halal screen: its debt is 1,008% of its market value, at or above the 33% limit. How we check
How has Claritev stock done over the past year?
Down 39.3% over the past twelve months, to $26.82. It traded between $13.47 and $54.87 and is 51.1% below its high.
Who are Claritev's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Claritev's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.